



**USAID**  
FROM THE AMERICAN PEOPLE

# ***Fundamentals of Clinical Trials and Human Subjects Protection at USAID***

***Global Health Mini-University  
2007***

Lee Claypool  
Cognizant Human Subjects Officer  
USAID  
Bureau for Global Health  
Office of Population and Reproductive Health  
Research, Technology and Utilization Division  
[lclaypool@usaid.gov](mailto:lclaypool@usaid.gov)



**USAID**  
FROM THE AMERICAN PEOPLE

## *Outline of Presentation*

- What are clinical trials and why are they needed?
- How and why does USAID fund clinical trials?
- What is the product development process?
- How are human subjects protected in clinical trials, etc?
- What are USAID regulations re human subjects protection?
- What are key issues and concepts for international human subjects research?
- Questions and discussion



**USAID**  
FROM THE AMERICAN PEOPLE

## ***Clinical Studies or Trials*** ***per International Conference on Harmonization***

Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy.



**USAID**  
FROM THE AMERICAN PEOPLE

# ***Scope of Health-Related Research and Development Activities at USAID***

***Report to Congress, Bureau for Global Health, May 2006***

**HIV/AIDS**: Vaccines; Microbicides

**Malaria**: Vaccines; Drugs, formulations, approaches

**Tuberculosis**: Drugs; DOT performance, access

**Reproductive Health and Family Planning**: New & improved contraceptives

**Maternal and Newborn Health**: Healthy pregnancy and birth outcomes; Maternal mortality measurements; New pregnancy and birth interventions; Neonatal research and care



**USAID**  
FROM THE AMERICAN PEOPLE

## ***Health-Related Research and Development, cont***

**Nutrition**: Vitamin A for deficiency prevention and control; Zinc for diarrhea therapy and prevention; Iron for anemia prevention and treatment; Community therapeutic and emergency care

**Acute Respiratory Infections**: Community-based treatment of childhood pneumonia; Reducing exposure to indoor air pollution

**Health Systems**: Performance assessment and financing; Pharmaceutical management; Quality assurance



**USAID**  
FROM THE AMERICAN PEOPLE

## ***Congressional Response to 2005 Report***

*“With its experience in the developing world, USAID does and should play a valuable role in facilitating international clinical trials, consolidating markets, and finding new opportunities to speed the discovery, development, and delivery of products to improve the lives of those in the developing world.”*



**USAID**  
FROM THE AMERICAN PEOPLE


# Product Development Process

## Pre-Clinical

## Phase I


## Phase II

10 years



Years of laboratory testing and screening of many compounds may result in a promising contraceptive drug.

1-2 years




Any possible toxicity of the compound is thoroughly checked and its pharmacology is assessed in animals.

1-2 years



Lack of toxicity and minimum effective dose are assessed in groups of 10 to 20 volunteers in different countries.

2 years



Long-term toxicity studies begin in animals as well as studies on reproduction, mutagenicity and carcinogenicity.

1-2 years



The first check of efficacy in humans involves up to a few hundred volunteers; acceptability studies begin.








**USAID**  
FROM THE AMERICAN PEOPLE

## *Product Development Process, cont*

### Phase III

### Phase IV


2-3 years	1 years	1-3 years	Indefinitely	Indefinitely
				
<p>Large-scale studies (1,000 subjects) start, lasting up to one year in various countries; acceptability studies continue.</p>	<p>Final arrangements are made for manufacture of the new contraceptive, and for its appropriate packaging.</p>	<p>All clinical and animal data are transmitted to national drug regulatory agencies, whose approval will be essential.</p>	<p>The finished product is supplied to family planning clinics, whose staff are trained in its delivery.</p>	<p>The drug becomes freely available: long-term surveillance guards against any rare adverse risks to health.</p>





**USAID**  
FROM THE AMERICAN PEOPLE

## ***Product Development Pipeline***



*(Many in, few out)*



**USAID**  
FROM THE AMERICAN PEOPLE

# ***Protection of Human Subjects in Research Supported by USAID***

USAID Guidance, Bureau for Global Health

Revised 12/26/2006

(A Mandatory Reference for ADS Chapter 200)

This is an explanation of selected relevant issues in Human Subjects Protection and how to apply the agency regulations appropriately for USAID-funded activities



**USAID**  
FROM THE AMERICAN PEOPLE

# ***Code of Federal Regulations***

Title 22 – Foreign Relations  
Chapter II – Agency for International Development  
Part 225 – Protection of Human Subjects

(Cite as 22 CFR 225)

This is the USAID statement of the Common Federal Policy for Protection of Human Subjects, and is often referred to as the “Common Rule”.



**USAID**  
FROM THE AMERICAN PEOPLE

## ***USAID Standard Provisions for NGO Recipients***

### Standard Provision: Protection of the Individual as a Research Subject (April 1998)

- (a) Safeguarding the rights and welfare of human subjects involved in research supported by USAID ***is the responsibility of the organization to which support is awarded.*** ... (***CHSO has oversight***, guidance, and interpretation responsibility.)
- (b) Recipient organizations must comply with USAID policy when humans are the subject of research ... and ***must provide “assurance”*** ... that they follow and abide by the procedures in the Policy. ...



**USAID**  
FROM THE AMERICAN PEOPLE

# ***Basic Principles of Human Research Subjects Protection***

*Per the “Belmont Report” of the President’s Commission for the Study of Ethical Programs in Medicine and Biomedical and Behavioral Research, 1979*

## **Human subjects research rests on 3 pillars of protection**

- Review of the research by a properly constituted ethical committee or Institutional Review Board (IRB)
- A meaningful assessment of the risks and benefits by the IRB, and
- A meaningful informed consent procedure for research subjects



**USAID**  
FROM THE AMERICAN PEOPLE

## ***Key Issues and Concepts in Human Subjects Protection***

- Defining Research – the Common Rule defines Research as “... a ***systematic investigation*** including research development, testing and evaluation designed to develop or contribute to ***generalizable knowledge***.”

Research *can* include: Experiments, observation studies, surveys, tests, recording other data for generalizable knowledge

Research generally does *not* include: Medical care, quality assurance or improvement, some public health practices such as outbreak investigations and disease monitoring, program evaluation, fiscal and program audits, journalism, fact-finding inquiries, etc



**USAID**  
FROM THE AMERICAN PEOPLE

## ***Key Issues and Concepts, cont***

- Defining Human Subjects – living individuals about whom an investigator obtains 1) data through intervention or interaction, or 2) identifiable private information
- Exempting certain research, e.g., 1) survey research, unless subjects can be identified and disclosure of responses places subject at risk, 2) collection or study of existing data or specimens, if sources are publicly available or if subjects cannot be identified, and 3) research on the process or outcomes of service delivery broadly



**USAID**  
FROM THE AMERICAN PEOPLE

## ***Key Issues and Concepts, cont***

- Achieving truly adequate informed consent
- Waiving or altering informed consent, e.g., when minimal risk
- Defining minimal risk
- Coordinating responsibilities for multiple-site research
- Ensuring continuing review and active oversight (compliance with USG requirements for IRBs)
- Promoting ethical behavior in research that is exempt





**USAID**  
FROM THE AMERICAN PEOPLE

## ***Key Issues and Concepts, cont***

- Ethics of research with children, prisoners, military personnel, persons with impaired decision-making capacity, and in emergency or disaster situations
- Coordinating all local regulations and guidance with USG requirements (HSP, importing, exporting, etc)
- Meeting FDA requirements for new product review and approval (re data needed, docs, GCP, etc)
- And many others ...



**USAID**  
FROM THE AMERICAN PEOPLE

## ***Additional Information***

- **Reports to Congress - Health-Related R&D Activities at USAID, June 2005 & June 2006**
- **USAID Standard Provision**
- **USAID Guidance**
- **22 CFR 225 – the “Common Rule”**
- **OHRP Website**
- **Mini-U Presentation**
- **Reference List**
- **USAID Cognizant Human Subjects Officer**



**USAID**  
FROM THE AMERICAN PEOPLE

## *Discussion*

- Questions
- Suggestions
- Comments
- Requests
- Further information
- Pearls